The good news here from the announcement is that nobody’s loosing jobs and all will just shift owners.  The over the counter consumer business sounds like they want to build it to compete with the over the counter J and J business to a degree.  It gets more complex all the time and of course this is all to increase sales and profits.  Details on the video below.  BD


Swiss pharmaceutical giant Novartis AG announced a series of multibillion-dollar deals Tuesday with other major pharmaceutical companies that it said would reduce sales but boost profitability, while affecting some 15,000 of its employees globally. image

The Basel, Switzerland-based company said it has agreed to buy GlaxoSmithKline plc's cancer-drug business for $14.5 billion, plus up to $1.5 billion more if certain milestones are met, and to divest most of its vaccines business to GSK for $7.1 billion, plus royalties.

The two drug makers also are creating a new consumer health care business through a joint venture. It combines Novartis' over-the-counter drug business with GSK's consumer business to create a new entity that would generate $10 billion a year in revenue. Novartis would own 36.5 percent of the new business, focusing on pain management, coughs and colds and dermatology.

All the deals between Novartis and GSK are timed to close simultaneously.

Separately, Novartis said it will sell off its animal health division to U.S.-based Eli Lilly & Co. for about $5.4 billion.,0,6687706.story#ixzz2zfMJApUm


Post a Comment